Effect of roxadustat on iron metabolism in patients with peritoneal dialysis: a real-world 24-week study

BACKGROUND: Roxadustat is an oral hypoxia inducing factor-prolyl hydroxylase inhibitor (HIF-PHI) that regulates iron metabolism in patients with chronic kidney disease (CKD) primarily by reducing hepcidin levels and mobilizing internal iron stores. More data are needed to demonstrate the efficacy of...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xuejie, Jia, Ruoyu, Zheng, Zhifang, Jiang, Luhua, Xu, Yizhou, Raj, Ashok, Sun, Dong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10629011/
https://www.ncbi.nlm.nih.gov/pubmed/37936193
http://dx.doi.org/10.1186/s40001-023-01465-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10629011/
https://www.ncbi.nlm.nih.gov/pubmed/37936193
http://dx.doi.org/10.1186/s40001-023-01465-0

Ejemplares similares